868P Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). - Wong, W.; Adkins, D.R.; Misleh, J.G.; Lorch, J.; Grewal, J.S.; Russell, J.; Cetnar, J.; Ho, A.L.; Chen, K.; Aysola, K.; Thomas, J. (Annals of Oncology, 2024)